ISSCR 2024 Copenhagen International Symposium Agenda:
Wednesday, 2 October 2024 | Thursday, 3 October 2024 | Friday, 4 October 2024
WEDNESDAY, 2 OCTOBER 2024
Note: All times listed are in Central European Summer Time (CEST)
9:00 AM – 10:05 AM: Opening Keynote
Room: Queen’s Hall
Sponsored by: Medicon Valley Alliance
9:00 AM - 9:02 AM | Welcome Remarks
Keith Alm, CEO, International Society for Stem Cell Research (ISSCR)
9:02 AM - 9:05 AM | Opening Remarks
Joachim Fruebis, Novo Nordisk, Denmark
9:05 AM - 9:15 AM | Program Introduction & Overview
Melissa K. Carpenter, Carpenter Consulting Corporation, USA
9:15 AM - 9:40 AM | Keynote Address
Heather Lombardi, OTP, CBER, FDA, USA
CMC CONSIDERATIONS FOR PSC-DERIVED CELL THERAPIES – A CBER PERSPECTIVE
9:40 AM – 10:05 AM | Keynote Address
Lotte Dahl Nissen, The Danish Medicines Agency, Denmark
HOW THE DANISH MEDICINES AGENCY FACILITATES THE ENTRY INTO THE REGULATORY LANDSCAPE FOR ADVANCED THERAPY MEDICINAL PRODUCTS
10:05 AM – 10:30 AM: Refreshment Break
Room: Foyer
10:30 AM – 12:00 PM: Clinical Trial Updates: PSC-Derived Therapies of the Eye
Room: Queen’s Hall
10:30 AM – 11:00 AM
Dennis Clegg, Regenerative Patch Technologies and UC Santa Barbara, USA
11:00 AM – 11:30 AM
Brian Culley, Lineage Cell Therapeutics, USA
OPREGEN®️: A SUSPENSION OF ALLOGENEIC RETINAL PIGMENT EPITHELIAL (RPE) CELLS IN PATIENTS WITH GEOGRAPHIC ATROPHY (GA) SECONDARY TO AGE-RELATED MACULAR DEGENERATION (AMD)
11:30 AM – 12:00 PM
Masayo Takahashi, Vision Care, Japan
SUSTAINABLE REGENERATIVE MEDICINE
12:00 PM – 1:30 PM: Lunch
Room: Foyer
1:30 PM – 3:15 PM: Clinical Trial Updates: PSC-Derived Therapies of the Brain
Room: Queen’s Hall
1:30 PM – 2:00 PM
Lorenz Studer, MSKCC & BlueRock Therapeutics, USA
PHASE 1 TRIAL OF HUMAN EMBRYONIC STEM CELL-DERIVED MIDBRAIN DOPAMINE NEURONS FOR PARKINSON’S DISEASE
2:00 PM – 2:15 PM
Andres Bratt-Leal, Aspen Neuroscience, USA
PRECLINICAL SAFETY AND EFFICACY OF DOPAMINE NEURON PROGENITOR CELLS DERIVED FROM PD DONOR-INDUCED PLURIPOTENT STEM CELLS
2:15 PM – 2:45 PM
Jun Takahashi, Kyoto University & CiRA, Japan
IPS CELL-BASED THERAPY FOR PARKINSON'S DISEASE: A KYOTO TRIAL
2:45 PM – 3:15 PM
Cory Nicholas, Neurona Therapeutics, USA
HUMAN INHIBITORY INTERNEURON CELL THERAPY FOR DRUG-RESISTANT EPILEPSY
3:15 PM – 3:45 PM: Refreshment Break
Room: Foyer
3:45 PM – 4:45 PM: Clinical Trial Updates: PSC-Derived Therapies Outside of the CNS
Room: Queen’s Hall
3:45 PM – 4:15 PM
Wolfram Zimmermann, Repairon & University Medical Center Göttingen, Germany
TISSUE ENGINEERED HEART REPAIR - FROM NON-HUMAN PRIMATES TO PATIENTS WITH ADVANCED HEART FAILURE
4:15 PM – 4:45 PM
Bob Valamehr, Fate Therapeutics, USA
THE DEVELOPMENT OF OFF-THE-SHELF IPSC-DERIVED CAR T-CELL THERAPY TO ELIMINATE A BROAD SPECTRUM OF PATHOGENIC CELLS IN HEMATOLOGICAL DISEASES IN THE ABSENCE OF CONDITIONING CHEMOTHERAPY